Sulu, Cem
Yumuk, Volkan Demirhan http://orcid.org/0000-0001-6463-4916
Article History
Received: 5 December 2023
Accepted: 15 January 2024
First Online: 4 February 2024
Declarations
:
: Volkan Yumuk has received funding from Eli Lilly for providing single advisor activity and Novo Nordisk for providing educational sessions or attending advisory boards. Cem Sulu has nothing to disclose.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.